EA202090071A1 - F-меченое соединение для диагностики рака предстательной железы и его применение - Google Patents

F-меченое соединение для диагностики рака предстательной железы и его применение

Info

Publication number
EA202090071A1
EA202090071A1 EA202090071A EA202090071A EA202090071A1 EA 202090071 A1 EA202090071 A1 EA 202090071A1 EA 202090071 A EA202090071 A EA 202090071A EA 202090071 A EA202090071 A EA 202090071A EA 202090071 A1 EA202090071 A1 EA 202090071A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prostate cancer
labeled compound
diagnostic
application
prostate
Prior art date
Application number
EA202090071A
Other languages
English (en)
Other versions
EA037781B1 (ru
Inventor
Дае Йоон Чи
Биоунг Се Ли
Со Йоунг Чу
Мин Хван Ким
Воон Дзунг Дзунг
Хиеон Дзин Дзеонг
Кио Чул Ли
Йонг Дзин Ли
Дзи Ае Парк
Ми Хиун Ким
Ран Дзи Йоо
Санг Моо Лим
Original Assignee
Фьючеркем Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фьючеркем Ко., Лтд. filed Critical Фьючеркем Ко., Лтд.
Priority claimed from PCT/KR2018/006869 external-priority patent/WO2018236115A1/ko
Publication of EA202090071A1 publication Critical patent/EA202090071A1/ru
Publication of EA037781B1 publication Critical patent/EA037781B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)

Abstract

Настоящее изобретение относится кF-меченому соединению и его применению. Соединение избирательно связывается с простат-специфическим мембранным антигеном (PSMA) и позволяет в короткие сроки получать четкие изображения рака предстательной железы при использовании в позитронно-эмиссионной томографии (ПЭТ).
EA202090071A 2017-06-19 2018-06-18 18f-меченое соединение для диагностики рака предстательной железы и его применение EA037781B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170077570 2017-06-19
KR1020180069590A KR102015355B1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
PCT/KR2018/006869 WO2018236115A1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도

Publications (2)

Publication Number Publication Date
EA202090071A1 true EA202090071A1 (ru) 2020-04-16
EA037781B1 EA037781B1 (ru) 2021-05-20

Family

ID=65008286

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090071A EA037781B1 (ru) 2017-06-19 2018-06-18 18f-меченое соединение для диагностики рака предстательной железы и его применение

Country Status (21)

Country Link
US (1) US10870629B2 (ru)
EP (1) EP3643707B1 (ru)
JP (1) JP6913968B2 (ru)
KR (1) KR102015355B1 (ru)
CN (1) CN110770212B (ru)
AU (1) AU2018288907B2 (ru)
CA (1) CA3067696C (ru)
CL (1) CL2019003727A1 (ru)
DK (1) DK3643707T3 (ru)
EA (1) EA037781B1 (ru)
ES (1) ES2912392T3 (ru)
HR (1) HRP20220557T1 (ru)
LT (1) LT3643707T (ru)
MX (1) MX2019015616A (ru)
MY (1) MY195426A (ru)
PH (1) PH12019502665A1 (ru)
PL (1) PL3643707T3 (ru)
PT (1) PT3643707T (ru)
RS (1) RS63205B1 (ru)
SG (1) SG11201911602RA (ru)
SI (1) SI3643707T1 (ru)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101664855B1 (ko) * 2008-08-01 2016-10-11 더 존스 홉킨스 유니버시티 Ｐｓｍａ-결합제 및 그의 용도
EP3505192A1 (en) 2011-08-05 2019-07-03 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
JP2014051442A (ja) * 2012-09-05 2014-03-20 Kyoto Univ 前立腺がんを診断可能な核医学イメージングプローブ
BR112015016585B1 (pt) 2013-01-14 2021-02-02 Molecular Insight Pharmaceuticals compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
EP3068747A1 (en) 2013-11-13 2016-09-21 GE Healthcare Limited Dual run cassette for the synthesis of 18f-labelled compounds
KR20150113801A (ko) * 2014-03-31 2015-10-08 한미약품 주식회사 Tak1 저해 활성을 갖는 피라진 접합고리 유도체
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
US11078166B2 (en) * 2015-08-13 2021-08-03 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
EP3493856B1 (en) 2016-06-28 2023-08-09 Cornell University 18f-labeled triazole containing psma inhibitors

Also Published As

Publication number Publication date
JP6913968B2 (ja) 2021-08-04
CL2019003727A1 (es) 2020-07-03
CN110770212A (zh) 2020-02-07
US20200207724A1 (en) 2020-07-02
PL3643707T3 (pl) 2023-06-12
DK3643707T3 (da) 2022-05-09
EA037781B1 (ru) 2021-05-20
MY195426A (en) 2023-01-20
LT3643707T (lt) 2022-05-25
SG11201911602RA (en) 2020-01-30
PT3643707T (pt) 2022-05-04
EP3643707B1 (en) 2022-02-23
EP3643707A1 (en) 2020-04-29
AU2018288907B2 (en) 2020-05-07
BR112019027183A2 (pt) 2020-06-30
HRP20220557T1 (hr) 2022-06-10
CA3067696A1 (en) 2018-12-27
CA3067696C (en) 2022-05-03
RS63205B1 (sr) 2022-06-30
ES2912392T3 (es) 2022-05-25
US10870629B2 (en) 2020-12-22
CN110770212B (zh) 2022-11-22
KR20180138169A (ko) 2018-12-28
KR102015355B1 (ko) 2019-10-23
SI3643707T1 (sl) 2022-06-30
EP3643707A4 (en) 2021-06-09
AU2018288907A1 (en) 2020-01-23
PH12019502665A1 (en) 2020-10-26
JP2020524175A (ja) 2020-08-13
MX2019015616A (es) 2020-02-26

Similar Documents

Publication Publication Date Title
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
EA202091540A1 (ru) Антитела к lilrb2
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CY1123790T1 (el) Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
EA201791167A1 (ru) Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
EA202092306A1 (ru) Анти-cd24 композиции и их применения
UY35964A (es) Anticuerpos humanos para pd?1
EA201690862A1 (ru) Соединения для позитронно-эмиссионной томографии
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
BR112019009172A2 (pt) formulações para radioterapia e diagnóstico por imagem.
MX2023005053A (es) Ligandos de psma para la formacion de imagenes y endorradioterapia.
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
EA201992883A1 (ru) АНТИТЕЛА К TrkB
MX2021014292A (es) Formulaciones de agentes de imagen de psma.
EA202090071A1 (ru) F-меченое соединение для диагностики рака предстательной железы и его применение
EA201891726A1 (ru) Лиганды для pet-визуализации тау-белков
EA201990319A1 (ru) Лиганды для pet-визуализации тау-белков
ES1122730U (es) Zapato con piezas y pisos recambiables.
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RU2015141959A (ru) Средство, обладающее одновременно протекторным действием в отношении здоровых органов и тканей и адъювантным действием при радио- и химиотерапии опухолей
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
RU2013111099A (ru) Способ комбинированного цифрового анализа гистотопографических срезов опухолевых образований молочной железы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM